Literature DB >> 18615077

Structure of the Ebola virus glycoprotein bound to an antibody from a human survivor.

Jeffrey E Lee1, Marnie L Fusco, Ann J Hessell, Wendelien B Oswald, Dennis R Burton, Erica Ollmann Saphire.   

Abstract

Ebola virus (EBOV) entry requires the surface glycoprotein (GP) to initiate attachment and fusion of viral and host membranes. Here we report the crystal structure of EBOV GP in its trimeric, pre-fusion conformation (GP1+GP2) bound to a neutralizing antibody, KZ52, derived from a human survivor of the 1995 Kikwit outbreak. Three GP1 viral attachment subunits assemble to form a chalice, cradled by the GP2 fusion subunits, while a novel glycan cap and projected mucin-like domain restrict access to the conserved receptor-binding site sequestered in the chalice bowl. The glycocalyx surrounding GP is likely central to immune evasion and may explain why survivors have insignificant neutralizing antibody titres. KZ52 recognizes a protein epitope at the chalice base where it clamps several regions of the pre-fusion GP2 to the amino terminus of GP1. This structure provides a template for unravelling the mechanism of EBOV GP-mediated fusion and for future immunotherapeutic development.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18615077      PMCID: PMC2700032          DOI: 10.1038/nature07082

Source DB:  PubMed          Journal:  Nature        ISSN: 0028-0836            Impact factor:   49.962


  60 in total

1.  Ebola virus can be effectively neutralized by antibody produced in natural human infection.

Authors:  T Maruyama; L L Rodriguez; P B Jahrling; A Sanchez; A S Khan; S T Nichol; C J Peters; P W Parren; D R Burton
Journal:  J Virol       Date:  1999-07       Impact factor: 5.103

2.  The finer things in X-ray diffraction data collection.

Authors:  J W Pflugrath
Journal:  Acta Crystallogr D Biol Crystallogr       Date:  1999-10

3.  Downregulation of beta1 integrins by Ebola virus glycoprotein: implication for virus entry.

Authors:  A Takada; S Watanabe; H Ito; K Okazaki; H Kida; Y Kawaoka
Journal:  Virology       Date:  2000-12-05       Impact factor: 3.616

4.  Pre- and postexposure prophylaxis of Ebola virus infection in an animal model by passive transfer of a neutralizing human antibody.

Authors:  Paul W H I Parren; Tom W Geisbert; Toshiaki Maruyama; Peter B Jahrling; Dennis R Burton
Journal:  J Virol       Date:  2002-06       Impact factor: 5.103

5.  Identification of the Ebola virus glycoprotein as the main viral determinant of vascular cell cytotoxicity and injury.

Authors:  Z Y Yang; H J Duckers; N J Sullivan; A Sanchez; E G Nabel; G J Nabel
Journal:  Nat Med       Date:  2000-08       Impact factor: 53.440

6.  Defective humoral responses and extensive intravascular apoptosis are associated with fatal outcome in Ebola virus-infected patients.

Authors:  S Baize; E M Leroy; M C Georges-Courbot; M Capron; J Lansoud-Soukate; P Debré; S P Fisher-Hoch; J B McCormick; A J Georges
Journal:  Nat Med       Date:  1999-04       Impact factor: 53.440

7.  Folate receptor-alpha is a cofactor for cellular entry by Marburg and Ebola viruses.

Authors:  S Y Chan; C J Empig; F J Welte; R F Speck; A Schmaljohn; J F Kreisberg; M A Goldsmith
Journal:  Cell       Date:  2001-07-13       Impact factor: 41.582

8.  Human asymptomatic Ebola infection and strong inflammatory response.

Authors:  E M Leroy; S Baize; V E Volchkov; S P Fisher-Hoch; M C Georges-Courbot; J Lansoud-Soukate; M Capron; P Debré; J B McCormick; A J Georges
Journal:  Lancet       Date:  2000-06-24       Impact factor: 79.321

9.  Critical role for the cysteines flanking the internal fusion peptide of avian sarcoma/leukosis virus envelope glycoprotein.

Authors:  S E Delos; J M White
Journal:  J Virol       Date:  2000-10       Impact factor: 5.103

10.  Core structure of the envelope glycoprotein GP2 from Ebola virus at 1.9-A resolution.

Authors:  V N Malashkevich; B J Schneider; M L McNally; M A Milhollen; J X Pang; P S Kim
Journal:  Proc Natl Acad Sci U S A       Date:  1999-03-16       Impact factor: 11.205

View more
  380 in total

1.  Antibody-Mediated Protective Mechanisms Induced by a Trivalent Parainfluenza Virus-Vectored Ebolavirus Vaccine.

Authors:  J Brian Kimble; Delphine C Malherbe; Michelle Meyer; Bronwyn M Gunn; Marcus M Karim; Philipp A Ilinykh; Mathieu Iampietro; Khaled S Mohamed; Surendra Negi; Pavlo Gilchuk; Kai Huang; Yuri I Wolf; Werner Braun; James E Crowe; Galit Alter; Alexander Bukreyev
Journal:  J Virol       Date:  2019-02-05       Impact factor: 5.103

2.  Point mutation in the glycoprotein of lymphocytic choriomeningitis virus is necessary for receptor binding, dendritic cell infection, and long-term persistence.

Authors:  Brian M Sullivan; Sébastien F Emonet; Megan J Welch; Andrew M Lee; Kevin P Campbell; Juan C de la Torre; Michael B Oldstone
Journal:  Proc Natl Acad Sci U S A       Date:  2011-01-26       Impact factor: 11.205

3.  Identification of a small-molecule entry inhibitor for filoviruses.

Authors:  Arnab Basu; Bing Li; Debra M Mills; Rekha G Panchal; Steven C Cardinale; Michelle M Butler; Norton P Peet; Helena Majgier-Baranowska; John D Williams; Ishan Patel; Donald T Moir; Sina Bavari; Ranjit Ray; Michael R Farzan; Lijun Rong; Terry L Bowlin
Journal:  J Virol       Date:  2011-01-26       Impact factor: 5.103

4.  Development and characterization of rabbit and mouse antibodies against ebolavirus envelope glycoproteins.

Authors:  Wu Ou; Josie Delisle; Krishnamurthy Konduru; Steven Bradfute; Sheli R Radoshitzky; Cary Retterer; Krishna Kota; Sina Bavari; Jens H Kuhn; Peter B Jahrling; Gerardo Kaplan; Carolyn A Wilson
Journal:  J Virol Methods       Date:  2011-04-13       Impact factor: 2.014

5.  Filoviruses require endosomal cysteine proteases for entry but exhibit distinct protease preferences.

Authors:  John Misasi; Kartik Chandran; Jin-Yi Yang; Bryden Considine; Claire Marie Filone; Marceline Côté; Nancy Sullivan; Giulia Fabozzi; Lisa Hensley; James Cunningham
Journal:  J Virol       Date:  2012-01-11       Impact factor: 5.103

6.  Structure of an antibody in complex with its mucin domain linear epitope that is protective against Ebola virus.

Authors:  Daniel Olal; Ana I Kuehne; Shridhar Bale; Peter Halfmann; Takao Hashiguchi; Marnie L Fusco; Jeffrey E Lee; Liam B King; Yoshihiro Kawaoka; John M Dye; Erica Ollmann Saphire
Journal:  J Virol       Date:  2011-12-14       Impact factor: 5.103

7.  Residues within the C-terminal arm of the herpes simplex virus 1 glycoprotein B ectodomain contribute to its refolding during the fusion step of virus entry.

Authors:  Sarah A Connolly; Richard Longnecker
Journal:  J Virol       Date:  2012-04-04       Impact factor: 5.103

8.  Inhibition of Marburg virus budding by nonneutralizing antibodies to the envelope glycoprotein.

Authors:  Masahiro Kajihara; Andrea Marzi; Eri Nakayama; Takeshi Noda; Makoto Kuroda; Rashid Manzoor; Keita Matsuno; Heinz Feldmann; Reiko Yoshida; Yoshihiro Kawaoka; Ayato Takada
Journal:  J Virol       Date:  2012-10-03       Impact factor: 5.103

9.  Tetherin-mediated restriction of filovirus budding is antagonized by the Ebola glycoprotein.

Authors:  Rachel L Kaletsky; Joseph R Francica; Caroline Agrawal-Gamse; Paul Bates
Journal:  Proc Natl Acad Sci U S A       Date:  2009-01-28       Impact factor: 11.205

10.  Model Building and Refinement of a Natively Glycosylated HIV-1 Env Protein by High-Resolution Cryoelectron Microscopy.

Authors:  Jeong Hyun Lee; Natalia de Val; Dmitry Lyumkis; Andrew B Ward
Journal:  Structure       Date:  2015-09-17       Impact factor: 5.006

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.